Marwan Sabbagh, MD
Neurology · Phoenix, AZNPI 1497748289
Payments from drug & device makers
Across 405 payments — averaging $2340.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$345K
- Eisai Inc.$148K
- Biogen$60K
- Acadia Pharmaceuticals Inc$56K
- F. Hoffmann-la Roche AG$49K
- Lilly USA, LLC$48K
- plus $242K from 29 others
Across 9 payments — averaging $1198.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$5K
- AbbVie$4K
- F. Hoffmann-la Roche AG$1K
- Biogen$876
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $344,733 |
| Eisai Inc. | 127 | $148,020 |
| Biogen | 40 | $60,460 |
| Acadia Pharmaceuticals Inc | 37 | $56,426 |
| F. Hoffmann-la Roche AG | 16 | $48,553 |
| Lilly USA, LLC | 37 | $48,017 |
| Novo Nordisk AS | 20 | $39,680 |
| Eli Lilly | 14 | $34,067 |
| Eisai CO., LTD. | 8 | $33,279 |
| Genentech USA, Inc. | 15 | $27,105 |
| Novo Nordisk | 13 | $21,963 |
| Genentech, Inc. | 11 | $15,027 |
| Roche Diagnostics Corporation | 7 | $12,382 |
| AbbVie(2 entities) | 9 | $11,168 |
| Janssen Global Services, LLC | 8 | $9,199 |
| Regeneron | 7 | $6,318 |
| Otsuka America Pharmaceutical, Inc. | 2 | $5,550 |
| Roche Diagnostics International Ltd | 2 | $4,890 |
| Corium, LLC | 2 | $4,058 |
| Merck | 1 | $3,375 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $3,295 |
| Beckman Coulter, Inc. | 2 | $2,750 |
| Lundbeck LLC | 4 | $2,152 |
| GE HealthCare | 3 | $2,028 |
| GSK | 2 | $1,788 |
| Roche Products Limited | 1 | $1,035 |
| Axsome Therapeutics, Inc. | 2 | $201 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $63 |
| C2n Diagnostics, LLC | 1 | $59 |
| Amgen | 1 | $39 |
| Grifols Shared Services North America, Inc. | 1 | $32 |
| Life Molecular Imaging Ltd | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$947,800 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Phoenix
- David WeidmanPhoenix$7.4M
- Stephen FlitmanPhoenix$4.4M
- Barry HendinPhoenix$4.4M
- Jeremy ShefnerPhoenix$3M
- Danielle CabralPhoenix$2.8M
- Suraj MuleyPhoenix$2.8M
- Todd SchwedtPhoenix$2.8M
- Todd LevinePhoenix$2.7M
- Anna BurkePhoenix$2.2M
- Maria OspinaPhoenix$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.